Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glutarate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | TSHR | P16473 | 5/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.50 |
| ▸ | GABRP | O00591 | 1/20 | 0.50 |
| ▸ | GABRD | O14764 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adipic Acid SCHEMBL11504533 | 0.93 | LMNA (0.73) | SLC22A6LMNATSHRNFKB1PMP22 | |
| Glutarate SCHEMBL29429789 | 0.89 | SLC22A6 (0.92) | SLC22A6LMNATSHRNFKB1PMP22 | |
| Glutarate SCHEMBL106178 | 0.88 | SLC22A6 (0.65) | SLC22A6LMNATSHRNFKB1PMP22 | |
| Glutarate SCHEMBL27737296 | 0.86 | SLC22A6 (0.85) | SLC22A6LMNATSHRNFKB1PMP22 | |
| Glutarate SCHEMBL27883522 | 0.86 | SLC22A6 (0.85) | SLC22A6LMNATSHRNFKB1PMP22 | |
| Succinic Acid SCHEMBL6906103 | 0.86 | LMNA (0.69) | SLC22A6LMNATSHRNFKB1PMP22 | |
| Glutarate SCHEMBL7414 | 0.86 | — | — | |
| Glutarate SCHEMBL6701735 | 0.86 | — | — | |
| Glutarate SCHEMBL27601182 | 0.86 | SLC22A6 (1.00) | SLC22A6LMNATSHRNFKB1PMP22 | |
| Glutarate SCHEMBL158774 | 0.86 | SLC22A6 (1.00) | SLC22A6LMNATSHRNFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11338036-B2 | Methods and compositions for the treatment and/or prevention of type 1 diabetes | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220016041-A1 | Once Daily Formulations Of Tetracyclines | CANADIAN IMPERIAL BANK OF COMMERCE, AS ADMINISTRATIVE AGENT (CA) | 2022-01-20 | — | — | US | disclosed |
| US-20220008535-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND/OR PREVENTION OF TYPE 1 DIABETES | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2022-01-13 | — | — | US | disclosed |
| US-10806700-B2 | Oral dosage forms for delivery of therapeutic agents | COVIDIEN LP (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190125683-A1 | Once Daily Formulations Of Tetracyclines | SHIRE LABORATORIES, INC. | 2019-05-02 | — | — | US | disclosed |
| US-20180344669-A1 | CONTROLLED DOSE DRUG DELIVERY SYSTEM | SHIRE LLC (US) | 2018-12-06 | — | — | US | disclosed |
| EP-2838518-B1 | METHOD OF TREATING ACNE | GALDERMA SA (CH) | 2018-02-21 | — | — | EP | disclosed |
| US-20170246127-A1 | CONTROLLED DOSE DRUG DELIVERY SYSTEM | SHIRE LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9713592-B2 | Matrix-based pulse release pharmaceutical formulation | MALLINCKRODT LLC (US) | 2017-07-25 | — | — | US | disclosed |
| US-20160338950-A1 | Oral Dosage Forms for Delivery of Therapeutic Agents | TYCO HEALTHCARE GROUP LP | 2016-11-24 | — | — | US | disclosed |
| US-6605300-B1 | For treatment of ADHD | SHIRE LABORATORIES, INC. | 2003-08-12 | — | — | US | disclosed |
| US-20030139385-A1 | Method of treating disorder related to high cholesterol concentration | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-24 | — | — | US | disclosed |
| US-20030124188-A1 | Oral pulsed dose drug delivery system | BURNSIDE BETH A (US) | 2003-07-03 | — | — | US | disclosed |
| WO-2003039480-A2 | METHOD OF TREATING DISORDER RELATED TO HIGH CHOLESTEROL CONCENTRATION | THE UNIVERSITY OF CHICAGO (US) | 2003-05-15 | — | — | WO | disclosed |
| US-20010055613-A1 | AMPHETAMINE SALT COVERED WITH ENTERIC RELEASE COATING | SHIRE LLC | 2001-12-27 | — | — | US | disclosed |
| US-6322819-B1 | AMPHETAMINE SALT COVERED WITH ENTERIC RELEASE COATING | SHIRE LABORATORIES, INC. | 2001-11-27 | — | — | US | disclosed |
| EP-1123087-A1 | ORAL PULSED DOSE DRUG DELIVERY SYSTEM | Shire Laboratories Inc. (US) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000023055-A9 | ORAL PULSED DOSE DRUG DELIVERY SYSTEM | SHIRE LAB INC (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-2000023055-A1 | ORAL PULSED DOSE DRUG DELIVERY SYSTEM | SHIRE LABORATORIES, INC. (US) | 2000-04-27 | — | — | WO | disclosed |
| CN-1247702-A | Effervescent pesticide for rice field | PESTICIDE FORM ENGINEERING TEC (CN) | 2000-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139385-A1 | Method of treating disorder related to high cholesterol concentration | CYP46A1, APOB, CYP27A1 | SLC22A6 523/4885LMNA 671/4885TSHR 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.